Get the Stockscreener App
8.41
0.12%
0.010
After Hours:
8.25
-0.16
-1.90%
Elicio Therapeutics Inc stock is traded at $8.41, with a volume of 131.02K.
It is up +0.12% in the last 24 hours and up +8.66% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$8.40
Open:
$8.4
24h Volume:
131.02K
Relative Volume:
1.16
Market Cap:
$145.15M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.3287
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
+10.51%
1M Performance:
+8.66%
6M Performance:
-10.53%
1Y Performance:
+11.84%
1-Day Range:
$8.05
$8.70
1-Week Range:
$7.505
$9.82
52-Week Range:
$4.60
$12.62
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
8.41 | 144.97M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way? - simplywall.st
How Elicio Therapeutics Inc. (ELTX) Affects Rotational Strategy Timing - Stock Traders Daily
Aug Setups: Does Elicio Therapeutics Inc offer margin of safetyNew Guidance & Smart Investment Allocation Tips - baoquankhu1.vn
(ELTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership - Yahoo Finance
Loss Report: Is SandRidge Energy Inc a stock for growth or value investorsJuly 2025 Trade Ideas & Safe Swing Trade Setups - baoquankhu1.vn
Retail Trends: Does Elicio Therapeutics Inc offer margin of safetyWall Street Watch & Technical Buy Zone Confirmation - baoquankhu1.vn
Why Elicio Therapeutics Inc. stock is seen as undervaluedEarnings Overview Summary & Risk Controlled Swing Alerts - bollywoodhelpline.com
Responsive Playbooks and the ELTX Inflection - Stock Traders Daily
Aug Volume: Will Elicio Therapeutics Inc benefit from AI trendsJuly 2025 Macro Moves & Weekly Setup with High ROI Potential - baoquankhu1.vn
Profit Review: What are the future prospects of Elicio Therapeutics Inc2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Elicio Therapeutics (ELTX) - The Globe and Mail
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why - Eastern Progress
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? - Eastern Progress
Why Elicio Therapeutics Inc. stock could benefit from AI revolutionJuly 2025 Catalysts & Safe Entry Trade Signal Reports - Улправда
Why CBLL stock attracts strong analyst attention - Улправда
How rising interest rates impact Elicio Therapeutics Inc. stock2025 Technical Overview & Reliable Volume Spike Trade Alerts - ulpravda.ru
KRAS Inhibitors Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Pfizer, Roche, Chugai, Genentech, Revolution Medicines, Eli Lilly, Merck, Taiho, Astex Pharma, Elicio - Barchart.com
How Elicio Therapeutics Inc. stock reacts to Fed rate cutsREITs Market Trends & Free High Margin Investment Plays - Улправда
Understanding the Setup: (ELTX) and Scalable Risk - Stock Traders Daily
How (ELTX) Movements Inform Risk Allocation Models - Stock Traders Daily
What is the fair value of Elicio Therapeutics Inc. stock nowJuly 2025 Drop Watch & Technical Entry and Exit Alerts - Улправда
Dividend Watch: Can Elicio Therapeutics Inc. stock hit record highs again2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - Улправда
Aug Decliners: Why Elicio Therapeutics Inc stock could rally in 2025July 2025 Setups & Verified Chart Pattern Signals - moha.gov.vn
Will Elicio Therapeutics Inc. stock benefit from green energy trendsWeekly Investment Summary & Reliable Entry Point Alerts - Улправда
Is Elicio Therapeutics Inc. stock ready for breakoutJuly 2025 Gainers & Entry Point Confirmation Alerts - bolumsonucanavari.com
FOMO Trade: Can Elicio Therapeutics Inc. stock hit record highs again2025 Geopolitical Influence & Entry and Exit Point Strategies - Улправда
How supply chain issues affect Elicio Therapeutics Inc. stockMarket Movers & Reliable Breakout Forecasts - DonanımHaber
Why Elicio Therapeutics Inc. stock could rally in 2025Earnings Risk Summary & Weekly High Potential Alerts - Улправда
Can Elicio Therapeutics Inc. stock withstand economic slowdownLong Setup & AI Forecasted Entry and Exit Points - Улправда
Elicio Therapeutics Earnings Notes - Trefis
Elicio Therapeutics (Nasdaq: ELTX) issues 157K options at $8.52 - Stock Titan
Understanding Momentum Shifts in (ELTX) - Stock Traders Daily
Elicio Therapeutics (ELTX) upgraded to buy: Here's why - MSN
Elicio’s cancer vaccine triggers broad anti-tumor immunity - Rare Cancer News
Elicio reports antigen spreading in 87% of evaluated cancer patients - Investing.com
Elicio reports antigen spreading in 87% of evaluated cancer patients By Investing.com - Investing.com Australia
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial - Yahoo Finance
Pancreatic Ductal Adenocarcinoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Elicio Therapeutics, Cend Therapeutics, Silenseed, Amplia - Barchart.com
How Elicio Therapeutics Inc. (9HA) stock reacts to stronger dollarQuarterly Market Summary & Safe Capital Allocation Plans - Newser
How Elicio Therapeutics Inc. (9HA) stock reacts to new regulations2025 Winners & Losers & Long-Term Growth Plans - Newser
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):